Changes in cardiac structure and function from 3 to 12 months after hospitalization for COVID‐19

Øvrebotten, Tarjei; Myhre, Peder L.; Grimsmo, Jostein; Mecinaj, Albulena; Trebinjac, Divna; Nossen, Magnus Berger; Andrup, Simon; Josefsen, Tony; Einvik, Gunnar; Stavem, Knut; Omland, Torbjørn; Ingul, Charlotte Björk

doi:10.1002/clc.23891

Cited by 13 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dyspnoea could also be a symptom of cardiac dysfunction. However, this was not found in a recent study presenting echocardiographic findings from our cohort [25].…”

Section: Discussioncontrasting

confidence: 98%

See 1 more Smart Citation

A prospective study of pulmonary outcomes and chest computed tomography in the first year after COVID-19

Lerum

Meltzer²,

Rodriguez³

et al. 2022

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

COVID-19 primarily affects the respiratory system. We aimed to evaluate how pulmonary outcomes develop after COVID-19 by assessing participants from the first pandemic wave prospectively 3- and 12-months following hospital discharge.Pulmonary outcomes included self-reported dyspnoea assessed with the modified Medical Research Council dyspnoea scale (mMRC), 6-minute walking distance (6MWD), spirometry, diffusion capacity of the lungs for carbon monoxide (DLCO), body plethysmography, and chest computed tomography (CT). Chest CT was repeated at 12 months in participants with pathological findings at 3 months. The WHO ordinal scale for clinical improvement defined disease severity in the acute phase.Of 262 included COVID-19 patients, 245 (94%) and 222 (90%) participants attended the 3- and 12-month follow-up, respectively. Self-reported dyspnoea and 6MWD remained unchanged between the two time points, while DLCOand total lung capacity improved (0.28 mmol min−1kPa−1, 95% CI (0.12–0.44), and 0.13 L, 95% CI (0.02–0.24), respectively). The prevalence of fibrotic-like findings on chest CT at 3 and 12 months in those with follow-up chest CT was unaltered. Those with more severe disease had worse dyspnoea, DLCO,åand TLC values than those with mild disease.There was an overall positive development of pulmonary outcomes from 3 to 12 months after hospital discharge. The discrepancy between the unaltered prevalence of self-reported dyspnoea and the improvement in pulmonary function underscores the complexity of dyspnoea as a prominent factor of long-COVID. The lack of increase in fibrotic-like findings from 3 to 12 months suggests that SARS-CoV-2 does not induce a progressive fibrotic process in the lungs.

show abstract

“…Dyspnoea could also be a symptom of cardiac dysfunction. However, this was not found in a recent study presenting echocardiographic findings from our cohort [25].…”

Section: Discussioncontrasting

confidence: 98%

“…Forty-one (21 %) participants reported dyspnoea at the 3-month visit and 34 (16 %) at the 12month visit (p=0. 25). Exercise capacity increased between the two time points, illustrated by an increase from mean 542 m (SD 123) to 570 m (SD 109) (p=0.01) on the 6MWD.…”

Section: Change In Pulmonary Outcomes Between 3-and 12-months After H...mentioning

confidence: 88%

A prospective study of pulmonary outcomes and chest computed tomography in the first year after COVID-19

Lerum

Meltzer²,

Rodriguez³

et al. 2022

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite the poor pre-discharge results of 6MWT and evidence of incomplete early physical functional recovery, we did not find these parameters to be independently predictive of preserved self-reported COVID-19 sequelae at 3 months when accounted for sex, age, and anthropometrical parameters, thus confirming the conclusion of Ladlow et al ( 40 ) about the lack of association between the objective functional limitations and the level of residual symptoms in the setting of PCS. We also have not found significant differences in cardiac structure and function both pre-discharge and after a one-month follow-up: patients with and without the PCS seemed to express similar changes that were in line with those reported before ( 41 , 42 ).…”

Section: Discussionsupporting

confidence: 86%

A prognostic model and pre-discharge predictors of post-COVID-19 syndrome after hospitalization for SARS-CoV-2 infection

Honchar,

Ashcheulova,

Chumachenko

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

BackgroundPost-COVID-19 syndrome (PCS) has been increasingly recognized as an emerging problem: 50% of patients report ongoing symptoms 1 year after acute infection, with most typical manifestations (fatigue, dyspnea, psychiatric and neurological symptoms) having potentially debilitating effect. Early identification of high-risk candidates for PCS development would facilitate the optimal use of resources directed to rehabilitation of COVID-19 convalescents.ObjectiveTo study the in-hospital clinical characteristics of COVID-19 survivors presenting with self-reported PCS at 3 months and to identify the early predictors of its development.Methods221 hospitalized COVID-19 patients underwent symptoms assessment, 6-min walk test, and echocardiography pre-discharge and at 1 month; presence of PCS was assessed 3 months after discharge. Unsupervised machine learning was used to build a SANN-based binary classification model of PCS development.ResultsPCS at 3 months has been detected in 75% patients. Higher symptoms level in the PCS group was not associated with worse physical functional recovery or significant echocardiographic changes. Despite identification of a set of pre-discharge predictors, inclusion of parameters obtained at 1 month proved necessary to obtain a high accuracy model of PCS development, with inputs list including age, sex, in-hospital levels of CRP, eGFR and need for oxygen supplementation, and level of post-exertional symptoms at 1 month after discharge (fatigue and dyspnea in 6MWT and MRC Dyspnea score).ConclusionHospitalized COVID-19 survivors at 3 months were characterized by 75% prevalence of PCS, the development of which could be predicted with an 89% accuracy using the derived neural network-based classification model.

show abstract

“…Cardiovascular manifestations of PACS are frequently seen in patients with pre-existing cardiovascular pathology [ 16 , 17 ]. Furthermore, the structural and functional changes appearing in PACS seem to be persistent over time as documented by some studies [ 18 , 19 ]. The three cases presented draw attention to the possibility of the existence of arrhythmic complications with malignant potential in patients in the post-acute phase of COVID-19 syndrome in patients with unknown cardiovascular pathology.…”

Section: Introductionmentioning

confidence: 95%

Rhythm Disturbances in Post-Acute COVID-19 Syndrome in Young Men without Pre-Existing Known Cardiovascular Disease—A Case Series

et al. 2023

View full text Add to dashboard Cite

Current data indicate the existence of post-acute COVID-19 syndrome frequently expressing as cardiovascular and respiratory health issues. The long-term evolution of these complications is not yet fully known or predictable. Among the most common clinical manifestations of post-acute COVID-19 syndrome are dyspnea, palpitations, and fatigue, in most cases being transient and without underlying any morphological or functional changes. A single-center retrospective observational study was performed on cases that had presented with new-onset cardiac symptoms post-COVID-19 infection. Records of three male patients without pre-existing chronic cardiovascular pathology who had presented for dyspnea, fatigue, and palpitations around four weeks post-COVID-19 acute phase were studied in detail. The three post-COVID-19 cases exhibited arrhythmic complications after completely healing from the acute phase of the infection. Palpitations, along with chest pain, and possible aggravation or appearance of dyspnea, with syncopal episodes, were found to be present. All the three cases were non-vaccinated against COVID-19 infection. Isolated case reports showing arrhythmic complications such as atrial fibrillation and ventricular tachycardia on a small number of patients with these complications indicate the need for arrhythmic evaluation of large groups of patients in the post-acute stage of the COVID-19 syndrome for a better understanding of the phenomenon and implicitly better care of these patients. It would also be useful to evaluate large groups of patients divided into vaccinated/non-vaccinated against COVID-19 categories to determine whether vaccination per se can provide protection in the occurrence of these types of complications.

show abstract

Changes in cardiac structure and function from 3 to 12 months after hospitalization for COVID‐19

Cited by 13 publications

References 37 publications

A prospective study of pulmonary outcomes and chest computed tomography in the first year after COVID-19

A prospective study of pulmonary outcomes and chest computed tomography in the first year after COVID-19

A prognostic model and pre-discharge predictors of post-COVID-19 syndrome after hospitalization for SARS-CoV-2 infection

Rhythm Disturbances in Post-Acute COVID-19 Syndrome in Young Men without Pre-Existing Known Cardiovascular Disease—A Case Series

Contact Info

Product

Resources

About